So the Trump situation has forced some hands. Rege
Post# of 148288
1. Will Cytodyn become attractive to a rival BP?
2. Would Nader be willing to sell it?
3. What is Cytodyn worth for ONLY HIV?
As far as I’m concerned cancer is a distant pipe dream I don’t even want to discuss it… I think we know that if Regeneron is even close to Leronlimab it’s game over as standard of care. I think the moment of decision is fast approaching and people need to start doing these calculations.